Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Br J Cancer. 2021 Feb;124(4):797-804. doi: 10.1038/s41416-020-01169-w. Epub 2020 Nov 19.
The impact of molecular aberrations on survival after resection of colorectal liver metastases (CLM) in patients with early-age-onset (EOCRC) versus late-age-onset colorectal cancer (LOCRC) is unknown.
Patients who underwent liver resection for CLM with known RAS, BRAF and MSI status were retrospectively studied. The prognostic impact of RAS mutations by age was analysed with age as a categorical variable and a continuous variable.
The study included 573 patients, 192 with EOCRC and 381 with LOCRC. The younger the age of onset of CRC, the greater the negative impact on overall survival of RAS mutations in the LOCRC, EOCRC, and ≤40 years (hazard ratio (HR), 1.64 (95% confidence interval (CI), 1.23-2.20), 2.03 (95% CI, 1.30-3.17), and 2.97 (95% CI, 1.44-6.14), respectively. Age-specific mortality risk and linear regression analysis also demonstrated that RAS mutations had a greater impact on survival in EOCRC than in LOCRC (slope: -4.07, 95% CI -8.10 to 0.04, P = 0.047, R = 0.08).
Among patients undergoing CLM resection, RAS mutations have a greater negative influence on survival in patients with EOCRC, more so in patients ≤40 years, than in patients with LOCRC and should be considered as a prognostic factor in multidisciplinary treatment planning.
在早发性结直肠癌(EOCRC)与晚发性结直肠癌(LOCRC)患者中,结直肠肝转移(CLM)切除术后分子异常对生存的影响尚不清楚。
本研究回顾性分析了已知 RAS、BRAF 和 MSI 状态的 CLM 患者行肝切除术的病例。以年龄为分类变量和连续变量分析 RAS 突变对年龄的预后影响。
本研究共纳入 573 例患者,其中 192 例为 EOCRC,381 例为 LOCRC。CRC 的发病年龄越小,LOCRC、EOCRC 和≤40 岁患者中 RAS 突变对总生存的负面影响越大(风险比(HR)分别为 1.64(95%置信区间(CI),1.23-2.20)、2.03(95% CI,1.30-3.17)和 2.97(95% CI,1.44-6.14))。年龄特异性死亡率风险和线性回归分析也表明,RAS 突变对 EOCRC 患者的生存影响大于 LOCRC(斜率:-4.07,95% CI-8.10 至 0.04,P=0.047,R=0.08)。
在接受 CLM 切除术的患者中,RAS 突变对 EOCRC 患者的生存有更大的负面影响,在≤40 岁的患者中比 LOCRC 患者更为显著,应在多学科治疗计划中作为预后因素考虑。